MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily

Opioid-Induced Disorders

Esophagus Disorder

Naloxegol

Placebo Oral Capsule

Temple University

Movantik for Opioid-Related Esophageal Disorders

The effect of MOVANTIK™ (Naloxegol) on motor function, categorized as a 25% (mmHg) improvement in IRP (Integrated Relaxation Pressure) on high resolution esophageal manometry from baseline to visit three, comparing study group to placebo control group.

Mean change from baseline to visit three in subject esophageal symptom scores according to the PAGI-SYM.

Mean change from baseline to visit three in subject esophageal symptom scores according to the McGill pain inventory.

Mean change from baseline to visit three in subject esophageal symptom scores according to the GERD symptom check list.

Mean change from baseline to visit three in subject esophageal symptom scores according to the chest pain symptom questionnaire.

Mean change from baseline to visit three in subject esophageal symptom scores according to the daily diary

The occurrence of adverse events and early withdrawal in study group when compared to placebo control group to determine safety and tolerability.

Mean change in patient-reported quality of life according to the SF-36

AstraZeneca

Hypercholesterolemia

3,5-Diiodothyropropionic acid (DITPA) therapy

Johns Hopkins Bayview Medical Center

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients

hyperhidrosis/שלשול

Movantik for Opioid-Related Esophageal Disorders

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע